Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?
Internal Medicine Journal · 2025
DOI: 10.1111/imj.16625 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Siehoon Lah und 1 weiteren Autor:innen. Beteiligte Einrichtung: Metabolism and Obesity Service, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Bariatric Surgery, Incretins, Obesity. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
The prevalence of obesity continues to increase worldwide. Obesity is associated with an increased risk of cardiometabolic and other diseases, reduced quality of life and shortened life expectancy. Highly effective therapies are required to achieve meaningful and sustained weight reduction to prevent, slow or reverse disease associated with obesity. Bariatric surgery is a highly effective intervention to induce weight loss, with observational data demonstrating durability of weight loss over 10 or more years. In addition, bariatric surgery improves cardiometabolic risk factors, including hyperglycaemia and type 2 diabetes, hypertension and dyslipidaemia. Observational data have shown a reduction in all‐cause mortality, cardiovascular events and mortality and a reduction in cancer risk and mortality in patients who have undergone bariatric surgery compared to matched patients who did not have surgery. The emergence of newer incretin agonists, particularly semaglutide and tirzepatide, have demonstrated remarkable efficacy in inducing and maintaining weight loss with ongoing use. As for bariatric surgery, incretin agonist therapies also improve type 2 diabetes outcomes, cardiovascular mortality and other obesity‐related complications, with new evidence emerging and long‐term outcome data awaited. This perspective compares bariatric surgery and incretin agonist therapy, assessing their relative efficacies in weight reduction, impact on obesity‐related complications, their respective risk profiles and considerations of cost‐effectiveness and equity of access. These comparisons seek to evaluate whether these increasingly popular medications could make bariatric surgery a thing of the past.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolism and Obesity Service, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
- Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Siehoon Lah, Samantha L Hocking
Zitieren
APA
Lah, S., & Hocking, S. L. (2025). Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?. Internal Medicine Journal. https://doi.org/10.1111/imj.16625
Vancouver
Lah S, Hocking SL. Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?. Internal Medicine Journal. 2025. doi:10.1111/imj.16625
BibTeX
@article{Lah2025,
author = {Lah, Siehoon and Hocking, Samantha L},
title = {Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.16625}
}
EUVIMED